首页 工具
登录
购物车

搜索结果

Search Results for " age-related macular degeneration "

29

抑制剂 & 化合物

1

天然产物

如果没找到您满意的产品或者您对产品有其他要求,可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Cat. No. Product Name Target Signaling Pathways
T9928 Ranibizumab

VEGFR Angiogenesis; Tyrosine Kinase/Adaptors
Ranibizumab 是一种人源化单克隆抗体片段,旨在靶向和抑制血管内皮生长因子 (VEGF),包括 VEGF110、VEGF121 和 VEGF165。 Ranibizumab 选择性靶向和中和 VEGF-A 同工型的能力使其成为湿性年龄相关性黄斑变性 (AMD) 研究和治疗策略的重要组成部分。
T28273L OT-551 HCl

OT-551 HCl(627085-11-4 Free base)

NF-κB NF-κB
OT-551 HCl 是一种 NF-Κb 抑制剂,是一种具有抗氧化特性的二取代羟胺可用于治疗白内障和老年性黄斑变性和地域性萎缩 (GA)。
T2706 Palomid 529

P529,SG 00529

Apoptosis; mTOR Apoptosis; PI3K/Akt/mTOR signaling
Palomid 529 (SG 00529) 是一种mTORC1和mTORC2复合体抑制剂,已用于研究治疗年龄相关性黄斑变性的试验。
T13157 TG 100801

TG100801,TG 100572

VEGFR; Src Angiogenesis; Tyrosine Kinase/Adaptors
TG 100801 是 VEGFr2 和 Src 家族(Src 和 YES)激酶的双重抑制剂,是治疗年龄相关性黄斑变性(AMD)的候选化合物。
T77600 Methyl-4-oxoretinoate

Apoptosis Apoptosis
Methyl-4-oxoretinoate 是一种合成的类视黄醇化合物,具有抗癌化合物,可可以诱导癌细胞分化和凋亡。Methyl-4-oxoretinoate 可用于治疗痤疮、牛皮癣和其他皮肤病。Methyl-4-oxoretinoate 具有治疗各种眼部疾病(如年龄相关性黄斑变性)的潜力。
T7493 AG-13958

AG-013958,N-[2-氟-5-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲唑-6-基]氨基]苯基]-1,3-二甲基-1H-吡唑-5-甲酰胺

VEGFR Angiogenesis; Tyrosine Kinase/Adaptors
AG-13958 (AG-013958) 是 VEGFR 酪氨酸激酶抑制剂,可用于年龄相关性黄斑变性 (AMD) 的脉络膜新生血管形成的研究。
T28273 OT-551

CPC 551,OT 551,CPC551,CPC-551

OT-551, a NF-κB inhibitor, is used potentially for the treatment of cataracts and age-related macular degeneration.
T27670 JNJ-26076713

JNJ26076713

JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.
T71988 Moxaverine hydrochloride

Moxaverine hydrochloride is a derivative of papaverine, a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma.
T39706 Pegaptanib sodium

Pegaptanib sodium, an RNA aptamer specifically targeting vascular endothelial growth factor (VEGF)-165, holds great promise for investigating neovascular age-related macular degeneration (AMD).
T9695L POT-4 acetate

POT-4 acetate (934461-40-2 free base)

Complement System Immunology/Inflammation
POT-4 acetate 抑制 Complement C3 的活化。 POT-4 acetate 可用于年龄相关性黄斑变性的研究。
TP1390 CEP dipeptide 1

CEP dipeptide 1, a potent angiogenic compound, exhibits robust activity in promoting angiogenesis. This compound is specifically implicated in the pathogenesis of age-related macular degeneration (AMD).
TP1464 Risuteganib hydrochloride

Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retin
T77016 Galegenimab

Galegenimab (FHTR 2163; RG 6147; RO 7171009),一种抗 HTRA1抗体片段。Galegenimab 可用于年龄相关性黄斑变性 (AMD) 研究。
T74867 UBX1325

UBX1325 是一种Bcl-xL 抑制剂,可促进衰老细胞的凋亡 (apoptosis)。UBX1325 是一种有效的抗衰老剂,可用于与年龄相关的眼部疾病的研究,如糖尿病性黄斑水肿 (DME)、年龄相关性黄斑变性 (AMD) 和糖尿病性视网膜病变 (DR)。
T76210 POT-4 TFA

POT-4 TFA (AL-78898A TFA),Compstatin 衍生物,有效抑制补体因子 C3 激活,适应于年龄相关黄斑变性研究。
T75156L Bevasiranib sodium

Bevasiranib sodium 是一种siRNA,可沉默产生血管内皮生长因子(VEGF)的基因。VEGF 在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用,而CNV 是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。
T75156 Bevasiranib

Bevasiranib 是一种siRNA,可沉默产生血管内皮生长因子(VEGF)的基因。VEGF 在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用,而CNV 是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。
T36620 ALK4290

ALK4290

ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].
T69452 AG-13958 monohydrochloride

AG-13958 monohydrochloride is the HCl salt of AG-13958 --- a VEGFA inhibitor potentially for the treatment of age-related macular degeneration. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF.
T13157L TG 100801 Hydrochloride

VEGFR Angiogenesis; Tyrosine Kinase/Adaptors
TG 100801 Hydrochloride is a prodrug to treat age-related macular degeneration. TG 100572 is a inhibitor of multi-targeted kinase(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src,
T74551 Avacincaptad pegol sodium

Avacincaptad pegol (ARC1905) 是一种靶向补体因子5 (C5)的核酸适配体,抑制C5剪切为C5a 和C5b。Avacincaptad pegol 被用于研究与年龄相关的黄斑变性(AMD)。
T76887 Rinucumab

Rinucumab (REGN 2176) 是一种单克隆抗体,是PDGF 的抑制剂。Rinucumab (REGN 2176) 可用于新生血管性年龄相关性黄斑变性的研究。
T76987 Tarcocimab

Tarcocimab (OG1953) 是一种人源化抗VEGFA 单克隆抗体 (IgG1 型)。Tarcocimab 可用于视网膜静脉阻塞 (RVO) 和湿性老年性黄斑变性 (AMD) 的研究。
T76814 Lampalizumab

Lampalizumab (RG 7417) 为靶向补体通路中补体因子 D (Factor D) 的人源单克隆抗体。通过结合外位点,该药物立体阻断因子 B 进入活性位点,用于老年性黄斑变性 (AMD) 研究。
T74552 Non-PEGylated/naked ARC1905

Non-PEGylated/naked ARC1905 是一种没有偶联PEG 的靶向补体因子5 (C5)的核酸适配体,抑制C5剪切为C5a 和C5b。Non-PEGylated/naked ARC1905 被用于研究与年龄相关的黄斑变性(AMD)。
T79010 Lp-PLA2-IN-12

Phospholipase Metabolism
Lp-PLA2-IN-12(compound 19)为一种Lp-PLA2抑制剂,主要应用于神经退行性疾病(如AD、青光眼、AMD)及心血管疾病(诸如动脉粥样硬化)的研究。
T79074 Lp-PLA2-IN-14

Phospholipase Metabolism
Lp-PLA2-IN-14(Compound 19)是一种选择性的Lp-PLA2抑制剂,其对rhLp-PLA2表现出较高亲和力,pIC50值达到8.4。该化合物主要适用于对抗与神经退行性疾病相关的研究,包括阿尔茨海默病(AD)、青光眼、年龄相关性黄斑变性(AMD),以及心血管疾病如动脉粥样硬化等。
T63192 Lp-PLA2-IN-10

Lp-PLA2-IN-10 是一种有效的脂蛋白相关磷脂酶 A2 (Lp-PLA2) 抑制剂。Lp-PLA2-IN-10 能够用于神经退行性相关疾病的研究,如阿尔茨海默病(AD)、青光眼、年龄相关的黄斑变性 (AMD),或者包括动脉粥样硬化等心血管疾病。Lp-PLA2 曾经被称作血小板活化因子乙酰水解酶 (PAF-AH),是一种参与脂蛋白脂质或磷脂水解的磷脂酶 A2。

化合物

Ranibizumab
Cat.No: T9928
Synonym:
Target: VEGFR
OT-551 HCl
Cat.No: T28273L
Synonym: OT-551 HCl(627085-11-4 Free base)
Target: NF-κB
Palomid 529
Cat.No: T2706
Synonym: P529,SG 00529
Target: Apoptosis, mTOR
TG 100801
Cat.No: T13157
Synonym: TG100801,TG 100572
Target: VEGFR, Src
Methyl-4-oxoretinoate
Cat.No: T77600
Synonym:
Target: Apoptosis
AG-13958
Cat.No: T7493
Synonym: AG-013958,N-[2-氟-5-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲唑-6-基]氨基]苯基]-1,3-二甲基-1H-吡唑-5-甲酰胺
Target: VEGFR
OT-551
Cat.No: T28273
Synonym: CPC 551,OT 551,CPC551,CPC-551
Target:
JNJ-26076713
Cat.No: T27670
Synonym: JNJ26076713
Target:
Moxaverine hydrochloride
Cat.No: T71988
Synonym:
Target:
Pegaptanib sodium
Cat.No: T39706
Synonym:
Target:
POT-4 acetate
Cat.No: T9695L
Synonym: POT-4 acetate (934461-40-2 free base)
Target: Complement System
CEP dipeptide 1
Cat.No: TP1390
Synonym:
Target:
Risuteganib hydrochloride
Cat.No: TP1464
Synonym:
Target:
Galegenimab
Cat.No: T77016
Synonym:
Target:
UBX1325
Cat.No: T74867
Synonym:
Target:
POT-4 TFA
Cat.No: T76210
Synonym:
Target:
Bevasiranib sodium
Cat.No: T75156L
Synonym:
Target:
Bevasiranib
Cat.No: T75156
Synonym:
Target:
ALK4290
Cat.No: T36620
Synonym: ALK4290
Target:
AG-13958 monohydrochloride
Cat.No: T69452
Synonym:
Target:
TG 100801 Hydrochloride
Cat.No: T13157L
Synonym:
Target: VEGFR
Avacincaptad pegol sodium
Cat.No: T74551
Synonym:
Target:
Rinucumab
Cat.No: T76887
Synonym:
Target:
Tarcocimab
Cat.No: T76987
Synonym:
Target:
Lampalizumab
Cat.No: T76814
Synonym:
Target:
Non-PEGylated/naked ARC1905
Cat.No: T74552
Synonym:
Target:
Lp-PLA2-IN-12
Cat.No: T79010
Synonym:
Target: Phospholipase
Lp-PLA2-IN-14
Cat.No: T79074
Synonym:
Target: Phospholipase
Lp-PLA2-IN-10
Cat.No: T63192
Synonym:
Target:
Cat. No. Product Name Target Signaling Pathways
T83915 Norbixin hydrate

Norbixin是一种在B. orellana中发现的类胡萝卜素,具有多样的生物活性。在无细胞测试中,它与过氧化物酶体增殖物激活受体γ (PPARγ)结合(Ki = 1.15 µM)。在心脑血管代谢综合征大鼠模型中,Norbixin (47.7 mg/kg) 能够减轻高血糖、高胰岛素血症和胰岛素抗性,降低血清脂质水平及心脏中硫代巴比妥酸反应性物质(TBARS)和谷胱甘肽(GSH)的水平。在胆固醇诱导的动脉粥样硬化兔模型中,它降低氧化型LDL和主动脉蛋白氧化水平,并减少动脉粥样硬化面积。Norbixin(每天0.1和1 mg/kg)减少汞诱导的大鼠肝细胞和白细胞DNA损伤。此外,它还能预防与年龄相关的黄斑变性(AMD)Abca4-/- Rdh8-/-小鼠模型中的光感受器退化。

天然产物

Norbixin hydrate
Cat.No: T83915
Synonym:
Target:
TargetMol Loading
联系我们
400-820-0310

上海市静安区江场三路238号8楼